Economic burden prior to COPD diagnosis: A matched case-control study in the United States

Respiratory Medicine

Volumn 102, Issue 12, 2008, Pages 1744-1752

  Akazawa, Manabu ^a   Halpern, Rachel ^b   Riedel, Aylin A ^b   Stanford, Richard H ^c   Dalal, Anand ^c   Blanchette, Christopher M ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Health Economics and Outcomes Research   (United States)

^c GLAXOSMITHKLINE   (United States)

^d LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Case control; COPD; Cost; Epidemiology; Healthcare; Utilization

Indexed keywords

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST OF ILLNESS; DISEASE COURSE; ECONOMIC ASPECT; FEMALE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HEALTH SERVICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; EPIDEMIOLOGIC METHODS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEX DISTRIBUTION; UNITED STATES;

EID: 55849095479     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2008.07.009     Document Type: Article

References (38)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; November 2006. Available at: [accessed January 5, 2007].
2. Coultas D.B., Mapel D., Gagnon R., and Lydick E. The health impact of undiagnosed airflow obstruction in a national sample of United States adults. Am J Respir Crit Care Med 164 (2001) 372-377
3. Hurd S.S. International efforts directed at attacking the problem of COPD. Chest 117 (2000) 336s-338s
4. National Heart, Lung, and Blood Institute. Morbidity and mortality chart book on cardiovascular, lung and blood diseases (2004), US Department of Health and Human Services, Public Health Service, National Institutes of Health, Bethesda, Maryland. http://www.nhlbi.nih.gov/resources/docs/cht-book.htm accessed January 5, 2007
5. Tockman M.S., Anthonisen N.R., Wright E.C., and Donithan M.G. Airways obstruction and the risk for lung cancer. Ann Intern Med 106 (1987) 512-518
6. Engstrom G., Wollmer P., Hedblad B., Juul-Moller S., Valind S., and Janzon L. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from 'men born in 1914', Malmo, Sweden. Circulation 103 (2001) 3086-3091
7. Malcolm C., and Marrie T.J. Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. Arch Intern Med 163 (2003) 797-802
8. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular disease? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 (2003) 1514-1519
9. Tirimanna P.R., van Schayck C.P., den Otter J.J., van Weel C., van Herwaarden C.L., van den Boom G., et al. Prevalence of asthma and COPD in general practice in 1992: has it changed since 1977?. Br J Gen Pract 46 406 (1996) 277-281
10. Steering Group Future Scenarios in Health Care. Chronic diseases in the year 2005. Part II: scenarios concerning CNSLD 1990-2005 (1990), Bohn Stafleu van Loghum, Houten/Antwerpen, The Netherlands
11. Dompeling E., van Grunsven P.M., Molema J., Verbeek A.L., van Schayck C.P., and van Weel C. Early detection of patients with fast progressive asthma or chronic bronchitis in general practice. Scand J Prim Health Care 10 2 (1992) 143-150
12. van den Boom G., van Schayck C.P., van Mollen M.P., Tirimanna P.R., den Otter J.J., van Grunsven P.M., et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. Am J Respir Crit Care Med 158 6 (1998) 1730-1738
13. Zielinski J., Bednarek M., and and Know the Age of Your Lung Study Group. Early detection of COPD in a high-risk population using spirometric screening. Chest 119 (2001) 731-736
14. Rennard S., and Farmer S. COPD in 2001: a major challenge for medicine, the pharmaceutical industry, and society. Chest 121 (2002) 113s-115s
15. Rennard S., Decramer M., Calverley P.M., Pride N.B., Soriano J.B., Vermeire P.A., et al. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 20 4 (2002) 799-805
16. van den Boom G., Rutten-van Molken M.P., Tirimanna P.R., van Schayck C.P., Folgering H., and van Weel C. Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J 11 1 (1998 Jan) 67-72
17. de Miguel Diez J., Izquierdo Alonso J.L., Molina Paris J., Rodriguez Gonzalez-Moro J.M., de Lucas Ramos P., and Gaspar Alonso-Vega G. Reliability of chronic obstructive pulmonary disease diagnosis by primary care physicians and pneumologists in Spain. Predictive factors. Arch Bronconeumol 39 5 (2003 May) 203-208
18. Bottema B.J.A.M. Diagnosis of CNSLD in general practice (1993), University of Amsterdam, Amsterdam p. 64
19. Kesten S., and Chapman K.R. Physician perceptions and management of COPD. Chest 104 (1993) 254-258
20. Jackevicius C.A., and Chapman K.R. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother 31 (1997) 160-164
21. Ferguson G.T. Screening and early intervention for COPD. Hosp Pract 33 4 (April 15, 1998) 67-84
22. Petty T.L. Scope of the COPD problem in North America; early studies of prevalence and NHANES III data: basis for early identification and intervention. Chest 117 (2000) 326s-331s
23. Allen-Ramey F.C., Markson L.E., Riedel A.A., Sajjan S., and Weiss K.B. Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone. Curr Med Res Opin 22 8 (2006) 1453-1461
24. Quam L., Ellis L.B., Venus P., Clouse J., Taylor C.G., and Leatherman S. Using claims data for epidemiologic research. The concordance of claims-based criteria with the medical record and patient survey for identifying a hypertensive population. Med Care 31 6 (1993) 498-507
25. Riedel A.A., Nelson M., Wallace K., Joseph-Ridge N., Cleary M., and Fam A.G. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10 6 (2004) 308-314
26. Stempel D.A., O'Donnell J.C., and Meyer J.W. Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol 109 3 (2002) 433-439
27. Stempel D.A., Riedel A.A., and Carranza Rosenzweig J.R. Resource utilization with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies in children with asthma. Curr Med Res Opin 22 3 (2006) 463-470
28. Elixhauser A., Steiner C., Harris D.R., and Coffey R.M. Comorbidity measures for use with administrative data. Med Care 36 1 (1998) 8-27
29. Agency for Healthcare Research and Quality. Comorbidity software, version 3.0. Available at: [accessed August 30, 2005].
30. Blough D.K., Madden C.W., and Hornbrook M.C. Modeling risk using generalized linear models. J Health Econ 18 2 (1999) 153-171
31. Manning W.G. The logged dependent variable, heteroscedasticity, and the retransformation problem. J Health Econ 17 3 (1998) 283-295
32. Jansson S.A., Lindberg A., Ericsson A., Borg S., Rönmark E., Andersson F., et al. Cost differences for COPD with and without physician-diagnosis. COPD 2 4 (December 2005) 427-434
33. West A., Strom B.L., and Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. In: Strom B.L. (Ed). Pharmacoepidemiology. 4th ed (2005), John Wiley and Sons, Ltd, Sussex, UK
34. Schneeweiss S., and Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58 4 (2005) 323-337
35. Charlson M.E., Pompei P., Ales K.L., and MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40 5 (1987) 373-383
36. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 6 (1992) 613-619
37. Schneeweiss S., Seeger J.D., Maclure M., Wang P.S., Avorn J., and Glynn R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 154 9 (2001) 854-864
38. Kennedy P. A guide to econometrics. 5th ed (2003), The MIT Press, Cambridge, MA